Relapsing multiple sclerosis (RMS) is the most common form of multiple sclerosis, characterized by episodes of new or worsening neurological symptoms. According to the World Health Organization, over 1.8 million people are affected by MS globally. Relapsing multiple sclerosis pipeline analysis by the publisher highlights significant advancements in small molecules, biologics, and gene therapies. The growing focus on targeted therapies, immunomodulators, and monoclonal antibodies is driving innovation in the relapsing multiple sclerosis pipeline. Moreover, with increased R&D investments, the clinical pipeline for relapsing multiple sclerosis is expected to grow steadily in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to relapsing multiple sclerosis.
Relapsing multiple sclerosis treatments aim to reduce relapses, delay disability progression, and control inflammation. These include disease-modifying therapies, monoclonal antibodies, oral agents, and injectable medications. In September 2024, the U.S. FDA approved Ocrevus Zunovo, the first and only twice-yearly, 10-minute subcutaneous injection for RMS. It offers flexible access without IV infrastructure, supported by ten years of efficacy data.
Bruton’s tyrosine kinase (BTK) inhibitors are emerging as a novel class in the relapsing multiple sclerosis drug pipeline. For instance, Roche’s investigational therapy, fenebrutinib, showed near-complete suppression of disease activity and no disability progression over 48 weeks in Phase II trial. It also demonstrated significant MRI lesion reduction, with a favorable safety profile consistent across multiple indications.
This product will be delivered within 3-5 business days.
Report Coverage
The Relapsing Multiple Sclerosis Pipeline Analysis Report by the publisher gives comprehensive insights into relapsing multiple sclerosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsing multiple sclerosis. The relapsing multiple sclerosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsing multiple sclerosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with relapsing multiple sclerosis treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to relapsing multiple sclerosis.
Relapsing Multiple Sclerosis Pipeline Outlook
Relapsing multiple sclerosis (RMS) is a chronic autoimmune disorder where the immune system attacks the protective myelin sheath covering nerve fibers in the central nervous system. This leads to inflammation and nerve damage, causing symptoms such as vision problems, muscle weakness, and cognitive impairment. RMS is characterized by flare-ups (relapses) followed by periods of partial or complete recovery (remissions).Relapsing multiple sclerosis treatments aim to reduce relapses, delay disability progression, and control inflammation. These include disease-modifying therapies, monoclonal antibodies, oral agents, and injectable medications. In September 2024, the U.S. FDA approved Ocrevus Zunovo, the first and only twice-yearly, 10-minute subcutaneous injection for RMS. It offers flexible access without IV infrastructure, supported by ten years of efficacy data.
Relapsing Multiple Sclerosis Epidemiology
Relapsing forms of multiple sclerosis (MS), especially relapsing-remitting MS (RRMS), involve recurrent episodes of neurological symptoms followed by recovery. According to a study published in 2025, an estimated 1.89 million people were living with MS globally in 2021, with a prevalence of 23.9 cases per 100,000 population. It is estimated that over 16,000 deaths are due to MS annually, with the highest burden in North America and Western Europe. The incidences are projected to increase by 2050.Relapsing Multiple Sclerosis - Pipeline Therapeutic Assessment
This section of the report covers the analysis of relapsing multiple sclerosis drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Monoclonal Antibodies
- Small Molecules
- Recombinant Fusion Proteins
- Peptides
- Gene Therapies
- Others
By Route of Administration
- Oral
- Parenteral
- Others
Relapsing Multiple Sclerosis Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III, with 59.26%, covers a major share of the total relapsing multiple sclerosis clinical trials. Phase II follows at 40.74%, and Phase IV holds at 25.93%. Phase I contributes 22.22%, and Early Phase I represents 4.88%. This ensures steady growth and therapeutic advancement in the relapsing multiple sclerosis pipeline.Relapsing Multiple Sclerosis Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the relapsing multiple sclerosis pipeline analysis include monoclonal antibodies, small molecules, recombinant fusion proteins, peptides, gene therapies, and others. The relapsing multiple sclerosis report provides a comparative analysis of the drug classes for each candidate in various phases of clinical trials for relapsing multiple sclerosis.Bruton’s tyrosine kinase (BTK) inhibitors are emerging as a novel class in the relapsing multiple sclerosis drug pipeline. For instance, Roche’s investigational therapy, fenebrutinib, showed near-complete suppression of disease activity and no disability progression over 48 weeks in Phase II trial. It also demonstrated significant MRI lesion reduction, with a favorable safety profile consistent across multiple indications.
Relapsing Multiple Sclerosis Clinical Trials - Key Players
The report for the relapsing multiple sclerosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed relapsing multiple sclerosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in relapsing multiple sclerosis clinical trials:- Novartis Pharmaceuticals
- Bristol-Myers Squibb
- Hoffmann-La Roche
- Sandoz Group AG
- Zenas BioPharma
- Genentech, Inc.
- TG Therapeutics, Inc.
- Sanofi
- Immunic AG
- Genentech, Inc.
Relapsing Multiple Sclerosis - Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for relapsing multiple sclerosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of relapsing multiple sclerosis drug candidates.Drug: BMS-986374
BMS-986374 (ozanimod), sponsored by Bristol-Myers Squibb, is currently being evaluated in a Phase IV study to determine its effectiveness and safety in Chinese adults with relapsing multiple sclerosis. This study is assessing the therapeutic impact of Zeposia, an oral S1P receptor modulator that selectively binds to S1P1 and S1P5, preventing lymphocyte migration from lymph nodes and potentially reducing inflammatory damage in the central nervous system.Drug: Fenebrutinib
Fenebrutinib is being evaluated in a Phase III study sponsored by Hoffmann-La Roche to compare its efficacy and safety against teriflunomide in adults with relapsing multiple sclerosis. The study aims to assess disability progression and relapse rates. Fenebrutinib is a highly selective, reversible oral BTK inhibitor, designed to modulate B-cell activity and innate immune responses with minimal off-target effects.Key Questions Answered in the Relapsing Multiple Sclerosis Pipeline Analysis Report
- Which companies/institutions are leading the relapsing multiple sclerosis drug development?
- What is the efficacy and safety profile of relapsing multiple sclerosis pipeline drugs?
- Which company is leading the relapsing multiple sclerosis pipeline development activities?
- What is the current relapsing multiple sclerosis commercial assessment?
- What are the opportunities and challenges present in the relapsing multiple sclerosis pipeline landscape?
- What is the efficacy and safety profile of relapsing multiple sclerosis pipeline drugs?
- Which company is conducting major trials for relapsing multiple sclerosis drugs?
- Which companies/institutions are involved in relapsing multiple sclerosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in relapsing multiple sclerosis?
Reasons To Buy This Report
The Relapsing Multiple Sclerosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for relapsing multiple sclerosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into relapsing multiple sclerosis collaborations, regulatory environments, and potential growth opportunities.This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Relapsing Multiple Sclerosis
4 Patient Profile: Relapsing Multiple Sclerosis
5 Relapsing Multiple Sclerosis: Epidemiology Snapshot
6 Relapsing Multiple Sclerosis: Market Dynamics
7 Relapsing Multiple Sclerosis: Key Facts Covered
8 Relapsing Multiple Sclerosis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Relapsing Multiple Sclerosis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Relapsing Multiple Sclerosis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Relapsing Multiple Sclerosis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Relapsing Multiple Sclerosis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Relapsing Multiple Sclerosis, Key Drug Pipeline Companies
